48% fibrosis improvement of at least one stage without worsening of NAS across all dose groups, with a 62% response rate for the 50mg dose group   28% fibrosis improvement of at least two stages across all dose groups, with a 38% response rate for the 50mg dose group   48% NASH resolution without